ArticleJournal of clinical laboratory analysis2025
Evaluating High Fluorescence Lymphocyte Count as a Predictor of Severe Dengue Infection.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue infection (DI) is a significant global health concern, with severe cases leading to plasma leakage, organ failure, and shock. Identifying reliable biomarkers for early risk stratification is crucial for improving patient management.
methodsThis descriptive cross-sectional study included 268 DI patients at 103 Military Hospital, Vietnam, from July 2022 to October 2023. Patients were classified into Non-Severe DI and Severe DI groups per the 2009 WHO dengue guideline. High Fluorescent Lymphocyte Count (HFLC), a parameter from the Sysmex hematology analyzer, was analyzed. HFLC% represents the proportion of high fluorescent lymphocytes among total WBCs, while HFLC# is these cells' absolute count (G/L). Statistical methods included Mann-Whitney U, Kruskal-Wallis, Chi-square tests, ROC curve analysis, and binary logistic regression.
resultsHFLC% and HFLC# were significantly elevated in Severe DI compared to Non-Severe DI (p < 0.001). HFLC% negatively correlated with platelet count and positively with liver enzymes (AST, ALT), suggesting an association with severe complications. ROC analysis showed that HFLC# (AUC = 0.913, p < 0.001, cut-off = 1.00 G/L) had 70.6% sensitivity and 90.8% specificity, while HFLC% (AUC = 0.833, p < 0.001, cut-off = 13.15%) had 70.6% sensitivity and 80.5% specificity for predicting severe DI.
conclusionElevated HFLC at admission is strongly associated with severe DI, with HFLC# demonstrating excellent predictive accuracy. These findings suggest that HFLC is a promising biomarker for early identification of high-risk dengue patients. Further large-scale validation is required to confirm its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.